Navigation Links
Oxford BioTherapeutics Licenses BioWa's POTELLIGENT® Technology for the Research and Development of its Therapeutic Antibodies in Cancer
Date:4/6/2011

PRINCETON, N.J., and OXFORD, England, April 6, 2011 /PRNewswire/ -- BioWa, Inc. (BioWa) and Oxford BioTherapeutics Ltd (OBT) today announced that they have entered into a license agreement to provide OBT with access to BioWa's patented POTELLIGENT® Technology platform for the development of antibody dependent cellular cytotoxicity (ADCC) enhanced antibodies.  

OBT intends to use POTELLIGENT® Technology to develop, manufacture and commercialize selected ADCC programs from its pipeline of preclinical antibodies for oncology which it has built based upon novel targets identified using its OGAP® proteomic database.

In return for the license, OBT will pay to BioWa undisclosed license fees, development and commercialization milestones and royalties on sales of any products that it commercializes.

"We are delighted to have access to BioWa's POTELLIGENT® Technology as part of our technology access portfolio as we build a pipeline of first-in-class therapeutic antibodies for cancer," said Christian Rohlff, CEO of OBT.  "Our strategy is to combine novel proprietary oncology targets with world-leading antibody technologies, such as POTELLIGENT® Technology, to develop highly efficacious new cancer drugs for patients with few treatment options."  

"The OBT cancer specific antibody portfolio has matured to an advanced stage where coupling to BioWa's POTELLIGENT® Technology enhances already promising anticancer agents and further enables our clinical development pipeline," commented OBT's Senior Vice President of Oncology, Jon Terrett.

"We are excited to expand our set of small company arrangements with OBT. In large part, our decision to partner with OBT was driven by our interest in novel therapeutic antibody targets identified through the OGAP® proteomic database," said Yasunori Yamaguchi, President and CEO of BioWa.

About POTELLIGENT® Technology

POTELLIGENT® Technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics.  POTELLIGENT® Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell.  Research shows that POTELLIGENT® Technology dramatically enhances ADCC activity of an antibody in vitro, and significantly increases potency and efficacy of the antibody in vivo.  A number of POTELLIGENT® antibodies are being investigated in human clinical trials.

About BioWa

BioWa is a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd., Japan's leading pharmaceutical and largest biotech company, and is the exclusive worldwide licensor of the AccretaMab® platform.  The AccretaMab® platform consists of POTELLIGENT® and COMPLEGENT® Technologies, creating a superior antibody molecule with enhanced ADCC and CDC activities.  BioWa is offering POTELLIGENT® and COMPLEGENT® Technologies to partners under a license to maximize the value of these technologies.  Together with Kyowa Hakko Kirin, BioWa is committed to promote ADCC/CDC enhanced monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases.  For more information about BioWa, visit its web site at http://www.biowa.com.

POTELLIGENT®, COMPLEGENT®, and AccretaMab® are the trademarks of Kyowa Hakko Kirin Co., Ltd.  All rights are reserved.  

About Oxford BioTherapeutics

Oxford BioTherapeutics (OBT) is focused on the development of targeted medicines for oncology.  OBT's strategy is to develop innovative antibody-based cancer drugs, with integrated diagnostics, against novel targets that it has discovered in its unique OGAP® proteomic database.  

OBT, through its alliances with the world leaders in antibody development, has been able to use its unique position to convert its novel targets into a highly attractive pipeline of therapeutic antibodies.  OBT's pipeline will deliver innovative and cost-effective medicines to fulfill major unmet patient needs in the field of cancer.  

OBT, a privately held company, was formed in 2004 and is based near Oxford, UK.

For further information, please see www.OxfordBioTherapeutics.com or www.oxbt.co.uk  

About OGAP®

The Oxford Genome Anatomy Project (OGAP®) database represents the world's largest proprietary collection of disease-associated proteins. OGAP® oncology contains proteomic data on 5,000 cancer membrane proteins combined with their genomic and clinical information derived from human blood and cancer tissue studies. OGAP® contains proprietary target information on three quarters of the entire human proteome. Over one million human protein fragments have been sequenced in OGAP in 50 different human tissues representing 60 diseases have been mapped to approximately 15,000 different genes and over eight million SNPs and haplotypes.

OGAP® is a registered trade mark of Oxford BioTherapeutics Ltd.


'/>"/>
SOURCE BioWa, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ICAP Ocean Tomo Announces Four Patent Sets From Oxford Instruments - Each Represents an Important Advancement in Technology
2. Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation
3. Oxford Finance Corporation Hires Debbie Baker to Support Life Science Business Development in Western North America
4. Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals
5. Oxford Finance Corporation and United Orthopedic Group, Inc. Close $20 Million Credit Facility
6. Oxford Finance Corporation Facilitates Entry for Reata Pharmaceuticals into Asian Markets
7. Oxford Finance Corporation Closes $25 Million Credit Facility with EUSA Pharma
8. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
9. CardioVascular BioTherapeutics Submits FDA Application for Fast Track Status for CVBT-141B, CVBTs Biological Treatment for Diabetes Patients
10. Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
11. Talecris Biotherapeutics Enrolls Patients in Clinical Trial Evaluating Two Doses of PROLASTIN®-C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best ... individuals in the United States and Canada wear eyeglasses. Once considered to be a ... and make a fashion statement. Even celebrities use glasses as a way of creating ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a ... and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is ... to some of the world’s leading providers of cereal and other breakfast foods. Its ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
Breaking Medicine News(10 mins):